| Names | |
|---|---|
| Preferred IUPAC name | 5-Fluoro-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4(1H,3H)-dione |
| Other names | Ro 21-9738 Furtulon |
| Pronunciation | /ˌdɒk.sɪˈflʊr.ɪˌdiːn/ |
| Identifiers | |
| CAS Number | 63843-89-0 |
| Beilstein Reference | 120895 |
| ChEBI | CHEBI:4646 |
| ChEMBL | CHEMBL16300 |
| ChemSpider | 72704 |
| DrugBank | DB03796 |
| ECHA InfoCard | 100.108.516 |
| EC Number | EC 3.2.2.6 |
| Gmelin Reference | 670013 |
| KEGG | D03894 |
| MeSH | Doxifluridine |
| PubChem CID | 5351145 |
| RTECS number | DW2980000 |
| UNII | 1S2N4N037B |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C9H11FN2O5 |
| Molar mass | 247.221 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.7 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | -1.2 |
| Vapor pressure | 5.8E-9 mmHg |
| Acidity (pKa) | 13.06 |
| Basicity (pKb) | 11.41 |
| Magnetic susceptibility (χ) | -8.17e-7 |
| Refractive index (nD) | 1.622 |
| Dipole moment | 5.61 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Doxifluridine: 431.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -531.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -689.5 kJ/mol |
| Pharmacology | |
| ATC code | L01BC07 |
| Hazards | |
| Main hazards | May cause cancer, harmful if swallowed, causes serious eye irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHSA |
| Signal word | Warning |
| Hazard statements | Hazard statements: H302, H312, H332 |
| Precautionary statements | Suspected of causing genetic defects. Suspected of causing cancer. |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | 115.2°C |
| Lethal dose or concentration | LD50 (rat, oral): 6350 mg/kg |
| LD50 (median dose) | LD50: 1000 mg/kg (mouse, oral) |
| NIOSH | NA |
| PEL (Permissible) | Not established |
| REL (Recommended) | 60-120 mg/kg/day |
| Related compounds | |
| Related compounds | Capecitabine Floxuridine 5-Fluorouracil Tegafur |
| Section | Industrial Commentary |
|---|---|
| Product Name & IUPAC Name |
Our technical teams refer to this product as Doxifluridine. The IUPAC name is 5-fluoro-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4(1H,3H)-dione. During manufacturing batch documents, the IUPAC name appears in full for regulatory clarity, especially for international registration and customs handling. |
| Chemical Formula |
The formula structure recognized by production is C9H11FN2O5. Throughout synthesis, process monitoring and material balance calculations are based on this stoichiometry. For impurity tracing and mass balance closure, the empirical formula provides the foundation for analytical methods in in-process and release testing. |
| Synonyms & Trade Names |
Within technical meetings and order systems, Doxifluridine is sometimes referenced using synonyms such as 5'-Deoxy-5-fluorouridine, or under international names like Furtulon and Docef. For regulatory registration, all known synonyms are cross-mapped within documents since these can impact legal interpretations during customs clearance and compliance reporting. Recognizing synonyms eliminates delays due to labeling variabilities across geographies and minimizes risk of shipment holds. |
| HS Code & Customs Classification |
Technical teams assign the product under HS Code 293359. Precise customs classification stems from the product’s categorization as a nucleic acid and its derivatives, containing a pyrimidine ring in the structure. Customs reporting conventions can differ regionally; quality teams advise double verification for borderline cases where trade agreements or dual-use regulations influence handling. Accurate HS coding is essential to manage import duties and regulatory documentation, ensuring smooth logistics and on-time delivery. |
Doxifluridine usually enters the plant as a solid, often as a crystalline powder. The form and color may shift between grades and synthesis methods; typical batches display white or off-white appearances. Odor remains negligible under all manufacturing conditions. Melting point and physical form are dependent on crystal lattice integrity, which is influenced by solvent choice during final recrystallization. Boiling and flash points do not directly guide plant safety, as Doxifluridine is manufactured and processed far below decomposition temperatures. Density values are rarely specification-defining in the API sector, but are monitored for consistency when bulk handling or preparing concentrated intermediates for synthesis validation.
Doxifluridine remains chemically robust under inert and dry storage. Trace moisture or pH fluctuation in process lines may accelerate minor hydrolytic degradation or byproduct formation, especially if storage integrates long pipeline holdups. Grades designed for oral formulations tolerate lower reactivity thresholds, so process contaminants are removed before final packaging. In-process reactivity is often controlled through temperature and pH, especially during final purification, to protect against deamination and ring cleavage.
Soluble in water and select polar organic solvents, with grade and particle size affecting dissolution kinetics during downstream formulation. Solubility values vary by polymorphic composition and lot-specific crystallinity. Plant-scale dissolution steps are benchmarked according to downstream requirements, with real-time monitoring for residue and particulates, as out-of-spec solubility dispersions can impact vaccine or tablet uniformity later on. Solution preparation for QC samples uses filtered water and validated solvent grades. Solubility data is always confirmed at the start of scale-up to avoid batchwise formulation pitfalls linked to feedstock differences.
Each batch is classified by end-use and regulatory destination. Specifications such as assay, moisture, individual impurity profile, and particle size distribution are negotiated per customer requirement or regional pharmacopoeial monographs. Typically, more stringent impurity and particle size controls are adopted for injectable or high-purity grades used in final drug products.
The identity and upper limits for process-related impurities, genotoxic species, and isomers vary with the synthetic route and plant campaign. Impurities are chiefly derived from over-reaction, catalyst decomposition, or solvent-related by-products, requiring dedicated analysis post-synthesis and after every purification stage. Release acceptance hinges on cumulative impurity load below internal and pharmacopeial guidelines. Impurity management strategies set for each grade and cannot be assumed interchangeable between markets.
Analytical releases deploy validated methods: HPLC for assay and impurity monitoring, GC where volatile residues dominate, and dedicated procedures for moisture and heavy metals when called for by customer or regulator. Only methods with full system suitability and calibration status are applied for product evaluation. The final release standard is subject to internal quality control criteria and customer requirements, with full analytical traceability archived batchwise.
Procurement teams select raw materials based on upstream traceability, supplier qualification, and impurity burden. Key starting materials must display consistent purity and low heavy-metal content, as feedstock variance directly shapes process yield and impurity fingerprint. Multistep synthesis favors suppliers supporting substantial documentation, with preference for plant-to-plant traceability in all GMP campaigns.
The synthetic approach typically entails coupling of sugar and fluorinated base moieties using protected intermediates. Pathway selection is dictated by available catalysis, cost efficiency, and impurity risk. As catalysts and solvents may introduce persistent microimpurities, in-process sampling screens for intermediates and side-products unique to the chosen route. Route changes between lines or campaign years trigger method revalidation and risk assessment.
Process engineers tightly regulate reaction temperature, order-of-addition, and reagent stoichiometry to constrain off-target products. Purification integrates multiple crystallization and liquid-phase extraction steps. Each batch document records temperature curves, pH adjustment points, mother liquor volumes, and solvent grades. In-process QC confirms endpoint purity and tracks removal of residual solvents and inorganic traces.
Each released batch passes through end-to-end documentation, ID testing, assay validation, and full impurity quantification. Results must meet customer and internal thresholds before shipment or transfer to formulation. Typical values depend on grade and application requirements, with customer acceptance ranges applied for export or specific regulatory regions. Batch release remains conditional on stability, traceability, and analytical closure.
Doxifluridine’s nucleoside core supports glycosylation, deprotection, and selective halogenation. Reaction specificity and yield often reflect catalyst quality and solvent phase. The selection of temperature, time, and base/acidity buffering is crucial for managing fluorination and reductive transformations. Residue management avoids late-stage racemization or isomer appearance during final conversion.
Batch records document any catalysts (metal-based, organocatalyst, enzymatic) and solvents for each reaction stage. Process conditions shift depending on targeted product grade, with injectable precursors using milder catalysts and tighter particulate control. Every change to catalyst regime or temperature profile in scale-up is requalified to prevent unexpected impurity profiles. Downstream mixing must account for solvent residue, which can alter product stability and storage safety.
Doxifluridine is designed for transformation to 5-fluorouracil and other therapeutic actives. Derivative handling and isolation protocols are tailored to the required purity and regulatory claims, with process adjustments for different formulations and combination products.
Production lots are stored in tightly sealed, light-resistant containers in low-humidity, temperature-controlled rooms. Temperature and humidity loggers track excursions, and any deviations from qualified ranges trigger risk assessment for batch integrity. Inert gas overlays may be deployed to avoid oxidative change when product remains in bulk storage awaiting packaging or export. Light protection is specified for longer-term, high-purity grades.
Compatible containers are selected to minimize absorption, static, and potential trace leaching. Polymers used are scrutinized for chemical compatibility and extractables, especially for batches intended for pharmaceutical applications. Compatibility checking forms part of change management for any new packaging introduction.
Shelf life is routinely verified by real-time and accelerated stability studies according to pharmaceutical standards. Typical shelf life depends on grade, storage, and packaging. Inspectors watch for color shifts, increased moisture, or breakdown impurities as early indicators of compromised stability or shelf life reduction. Stability failures demand full CAPA and investigation for both process and packaging sources.
Classification under local and global GHS standards aligns with observed toxicity and risk studies by batch. Hazard labeling and safety documentation are updated when new data emerges or regulatory threshold shifts. Only validated and officially published rating systems are deployed on shipping and manufacturing labels.
Operations teams apply precautionary procedures dictated by experimental toxicity outcomes, focusing on dermal, inhalation, and accidental ingestion risk mitigation. Hazard statements derive from real accident or spillage investigations and regulatory audit feedback. All staff receive product-specific PPE training during campaign switches or after any route modification.
Toxicological assessments stem from controlled trials, literature, and mandatory reporting. Precise metrics and permissible exposure levels adjust as more data from regulatory audits and industry collaboration become available. Statements are never extrapolated beyond the validated study context; plant controls align to current toxicological consensus.
Handling practices prioritize dust and aerosol control in all open operations. Engineering controls, including containment, ventilation, and transfer system lockouts, are deployed based on cumulative exposure risk to operators. Site-specific exposure control levels are set from measured air sampling and are adjusted upon process change or introduction of new equipment. Any revision to exposure levels triggers procedural updates and retraining across shifts.
At the manufacturing level, Doxifluridine supply hinges on reactor capacity, scheduled campaign durations, and real-time maintenance cycles. Flexibility exists for both small custom lots and larger multi-ton batches, depending on demand signals and production slot allocation. Yield variations depend strongly on route purity control and impurity cut-off limits established in quality agreement stages. Batch overlap is restricted based on segregation of drug substance from unrelated APIs in shared plants.
For Doxifluridine, standard MOQ aligns with downstream formulation batch size and throughput of isolation equipment. Lead times depend on synthesis route complexity and pre-ordering of regulated intermediates. Accelerated delivery options are feasible for repeat customers with validated quality documentation and pre-approved packaging configurations. Logistics lead times are impacted most by freight mode selection and import control at destination ports.
Pack choices are defined primarily by transportation risk, anticipated storage timeline, and target release assay. Standard packaging includes multi-layer barrier drums, with options ranging from low-kg units for R&D use to lined fiber drums suitable for shipment under temperature-controlled conditions. Custom solutions enabling nitrogen blanketing or tamper-evident sealing become necessary where photo-oxidation or cross-contamination risk is flagged in project risk assessment.
Terms reflect both international regulatory requirements and anti-diversion controls. Export documentation must substantiate end-use declaration and recipient authentication, especially where Doxifluridine classification triggers state control. Payment terms are set in line with supply relationship maturity, with L/C, advanced TT, or milestone partial payments adopted per mutual risk assessment and compliance diligence.
The largest cost driver for Doxifluridine is raw material input, primarily due to the specialized nucleoside base and associated protected intermediates. Key precursors include fluorinated pyrimidine derivatives, with pricing tied to global supply concentration and licensing status. Regulatory-compliant suppliers with low impurity profiles command premium prices. Licensing fees, multi-step synthesis requirements, and hazardous waste disposal contribute additional cost layers.
Global shortages or supply bottlenecks—for example, temporary plant shutdowns or export restrictions in the origin country—drive up input pricing. Exchange rate volatility affects costs for raw materials sourced in USD or JPY. Pricing sees spikes during enforcement of new environmental controls, with any tightening in controlled substance regulation lifting compliance costs and affecting net margin.
Doxifluridine pricing separates based on grade, especially differentiation between intermediate use (non-GMP) and drug substance (cGMP or GMP). Higher purity grades carry higher cost per kg, with additional layers for full traceability and customer-audited release testing. Certification (e.g., CEP, DMF submission) demands batch-level documentation, directly reflected in price. Packaging size further introduces tiered pricing; larger drums provide marginal discount per kg relative to small lot packaging meant for R&D or reference standards.
Doxifluridine demand is dominantly shaped by active pharmaceutical manufacturing in East Asia and contract manufacturing for Western markets. Restrictions on precursor formulation and region-specific registration requirements concentrate capacity in facilities with both export-compliant licensing and multi-market regulatory dossiers. On the demand side, hospital procurement cycles and localization of generic production in India and China shape downstream offtake.
US requirements focus on import traceability and controlled-substance compliance, typically preferring US FDA-inspected source plants and DMF-backed materials. EU buyers mandate GMP traceability and CEP documentation, with priority on single-source consistency for generics manufacturing. Japan demands domestic traceability and precise control of process impurities, often leveraging partnerships with established local CMOs. In India and China, price competition pressures margins, but volumes stay high due to large-scale generic production.
Looking toward 2026, moderately upward price pressure persists from steady demand in oncology APIs and potential tightening in nucleoside intermediate supplies. Compliance-driven price layering accelerates in regulated markets. Raw material volatility—caused by either supply disruptions or stricter environmental enforcement in manufacturing hubs—may drive quarterly fluctuations. Stable single-digit percent annual increases can be projected in tightly regulated economies, with greater variability seen in unconsolidated import markets.
Pricing and market commentary derive from internal benchmarking of supplier offers, historical data out of trade statistics, feedback from large volume buyers, and process route economics consistently updated in line with compliance changes and raw material audits.
Year-on-year, several manufacturing regions reported licensing reviews for core fluorinated intermediates linked to anti-diversion controls. Capacity expansion in select Asian plants provided added stability, though intermittent supply disruptions from environmental inspections led to temporary allocation of export lots for scheduled repeat customers.
Enhanced scrutiny under anti-counterfeiting regulations increased documentation requirements in final batch release. Regulatory agencies in Europe and North America implemented tighter review protocols for CEP renewals tied specifically to new impurity guidelines, pushing manufacturers to maintain higher internal release specifications.
Manufacturers upgraded internal batch reconciliation systems and pursued expanded vendor audits for precursors flagged by recent import controls. Greater focus landed on in-process purification and final batch documentation to ensure readiness for regulatory queries. Technical transfer and risk-sharing contracts saw more interest, especially for buyers needing rapid response to local regulatory updates or customized compliance support.
Doxifluridine appears almost exclusively in the pharmaceutical field, mainly as an active pharmaceutical ingredient for oral and injectable cancer therapeutics. Contract development and manufacturing organizations (CDMOs) and pharmaceutical formulation houses source this compound for the synthesis of anti-tumor drugs, especially in the treatment of gastric, colorectal, and breast carcinomas. Clinical trial material supply chains and generic drug manufacturers often require grade-specific lots for regulatory submission and process validation.
| Application | Common Grades Used | Typical Grade-Dependent Considerations |
|---|---|---|
| API Synthesis (Direct Formulation) | Pharmaceutical Grade | Grades must show strict control of residual solvents, defined polymorphic form, trace metal clearance, and comprehensive impurity profiling per ICH Q3A/B guidelines. Polymorph control and water content specification influence downstream tabletability and encapsulation stability. |
| Preclinical/Clinical Trials | GMP-Compliant Pilot Scale Lot | Batch traceability, stability data, and product consistency are prioritized. Material qualification must match the clinical protocol and IND content requirements. |
| Research & Development | Laboratory/Literature Grade | Focus is mostly on purity and characterization. Some flexibility in impurity profile may be tolerated if clear documentation supports research reproducibility. |
Doxifluridine performance in finished dosage forms hinges on several characteristics:
End-use determines the batch requirements. API synthesis for regulatory markets always requires pharmaceutical grade with full GMP documentation. Early-stage R&D can accept literature-grade when coupled with certificate of analysis and method transparency.
Each market’s regulations, such as US FDA, EMA, or NMPA, establish baseline acceptance criteria. Some agencies request extended impurity profiling or added stability data. Refer to registration guidelines specific to your application country and application class.
Final product dosage form, sensitivity of patient population, and therapeutic window all shape the minimum acceptable purity. For generic drug filings or new drug applications, sponsors often provide target impurity limits driven by toxicology and pharmacokinetics.
Lab development and early clinical phases seldom require large campaigns, reducing impact from process scale-up variability. For commercial products, cost-per-kilogram and annual supply stability gain importance, especially across multi-year tenders requiring ongoing batch release testing and stability studies.
Pilot-scale or sample batch evaluation with in-house method suitability tests allows early detection of mismatches in purity, particle size, moisture, or solubility. Qualification lots enable risk mitigation in the final process transfer and ensure compatibility with your formulation and analytical routines.
Every released batch of Doxifluridine undergoes internal quality management processes anchored in recognized standards. Industrial production is backed by ongoing compliance with Good Manufacturing Practice protocols, validated through frequent internal audits and third-party inspections. Certification status is audit-schedule-dependent and extends to all full-scale manufacturing installations handling this active compound.
Batch-to-batch consistency is managed by detailed operational control across synthesis, isolation, and purification stages. Staff training is updated for any revision of external guidelines or relevant regulatory stipulations—especially in markets where updated or region-specific quality frameworks replace older protocols. Certification coverage varies if product is made at different facilities or under custom protocols.
Pharmaceutical-grade Doxifluridine is supplied with Drug Master File support and, where required, with regulatory accreditation from health authorities. Specifications differ by export region and customer submission requirements. Certificates of Analysis reflect defined test methods for product identity, content, and known/controlled impurities. Any specialized certification, such as compliance with a monograph from pharmacopeias, must be predetermined in purchase agreements due to variability in test standards between regions.
Impairment by route-specific impurities is minimized by strict purification and in-process controls at points identified as impurity-generation risks. Process lines are equipped for traceability to ensure rapid response upon any quality deviation, supporting pharmacovigilance and batch recalls if triggered by downstream reports.
Document packs are tailored by delivery grade and by end-user regulatory expectations. Technical documentation includes batch release reports, process flow data when cleared for disclosure, and analytical certifications. Reports listing critical control points highlight where parameter drifts would affect compliance or downstream synthesis integration. Additional bespoke documents, such as stability updates or impurity trend analyses, are provided per written request—approvals for access governed by confidentiality or compliance restrictions.
Long-term supply contracts can be structured to align with your forecasted demand profile. Our principal Doxifluridine plants operate continuous or campaign-based synthesis lines according to volume, minimizing lead time and managing raw material exposure risks. Stability in production flow stems from multi-source precursor qualification and buffer storage for key intermediates. Any necessary change in production plan—caused by regulatory, logistical, or market events—is openly discussed with long-term clients prior to implementation.
Production lines are dimensioned to sustain supply for both high-frequency and project-based procurement models. Key infrastructure includes segregated lines for critical process steps, ensuring cross-contamination risks are eliminated between grades or parallel campaigns. Supply continuity depends on precursor market availability as well as on ongoing environmental and safety inspections; adjustments to capacities are communicated ahead of time to anchor customer planning.
We recommend demand forecast sharing so production scheduling can match expected usage, reducing exposure to sudden supply chain disturbances. Emergency stock programs are defined by volume agreement and facility capacity constraints.
Samples can be provided in accordance with documented requests. Preferred process: specify intended use, required characterization, and documentation needs. Sample distribution follows internal retention sample procedures, including detailed traceability for all aliquoted volumes. All sample requests pass QA review under the same release parameters as commercial product, unless a non-conforming or experimental batch is specifically requested for R&D feedback. Shipping of regulated samples conforms to legal classification for transport safety.
Order structures can range from blanket agreements to one-time spot deliveries. Flexibility stems from modular process design: campaign sizes and grade adjustments are set by commercial or development needs. We accommodate both fixed-quantity supply and volume-adjusted models, with price and allocation determined by annual volume, quality grade, and delivery frequency.
We support joint process audits with long-term partners and welcome co-development of custom grades. Lines of communication remain open for technical query resolution, process change notices, and quality negotiation when end-use requirements evolve. Routine reevaluation of supply models is standard practice in response to changing market or technology landscapes.
Doxifluridine continues to attract significant research attention as a prodrug of 5-fluorouracil, with most industrial laboratories focusing on optimizing synthesis efficiency and impurity control. Efforts concentrate on reducing residual solvent levels and streamlining purification steps, as even minor process changes can cause shifts in impurity profile. Batch-to-batch reproducibility and maintaining high assay values remain focal points. Most recent exploration involves co-crystallization strategies for stability, as well as development of oral dosage forms that maximize bioavailability without increasing toxicity.
New clinical protocols are driving demand for Doxifluridine in solid tumor regimens, particularly as adjuvant therapy. Opportunities are arising in markets with evolving regulatory landscapes favoring prodrug approaches. Investigation is also ongoing in controlled-release formulations aiming to improve patient compliance and modulate plasma concentrations, particularly for non-hospital administration. Application-specific requirements for particle size, moisture content, and polymorph form are becoming more stringent as more downstream processors require direct compressibility for oral solid dose manufacturing.
Key technical hurdles include impurity management, mainly related to degradation and reaction byproducts formed under process or storage stress. Advanced chromatography techniques now provide robust quantification of trace-level impurities, but reproducible control at the manufacturing scale challenges operators, especially during scale-up or route transfer. Recent breakthroughs from process intensification studies showed that continuous flow transformations allow gentler temperature control and reduce impurity formation compared to classic batch synthesis. Nonetheless, not all grades can be produced efficiently by flow methods due to equipment or raw material limitations, necessitating hybrid approaches for certain regional demands.
Rising adoption of fluoropyrimidine-based chemotherapies is prompting increased capacity planning for Doxifluridine. Growth rates tend to follow changes in treatment regimen guidelines in Asia-Pacific and select Latin American markets, as generic approvals and expanding indications alter procurement cycles. Market volatility often occurs when patent cliffs near, as downstream partners begin qualifying alternative suppliers. New market entries typically require demonstration batches with data packages tailored to local regulatory standards—which include stability, impurity, and trace metal data—each varying by territory.
Production technology is shifting toward integrated, closed-loop monitoring, with inline analytics for critical parameters such as reaction pH, temperature, and impurity spikes. Automation at this level permits finer process control, particularly helpful in large-volume lots for export markets. Maintenance of consistency across campaigns, especially under multipurpose plant conditions, puts pressure on real-time monitoring and immediate intervention protocols. Manufacturers adopting these systems see reductions in out-of-specification batches and faster cycle times, with cost advantages in energy consumption and solvent recovery.
Solvent reduction and recycling form a central component of greener manufacturing for Doxifluridine, both for regulatory compliance and operational efficiency. Specific attention is given to minimizing tetrahydrofuran and other class II solvent residues, using aqueous workups and more selective crystallization. At the sourcing stage, evaluation of bio-derived raw materials is ongoing amongst larger sites as a step to reduce fossil-based feedstocks. Downstream, efforts are focused on reducing active pharmaceutical ingredient loss in waste streams, with improved capture and recovery practices implemented based on batch yield analyses.
Direct access to technical support enables project teams to troubleshoot key process parameters, refine impurity profiles, and adapt manufacturing protocols to specific application goals. Most queries focus on optimizing dilution, solubility, or blending characteristics for integration into different oral dosage manufacturing lines. Site engineers provide advice on pre-mix procedures, moisture control during storage, and in some cases, on customized sampling protocols for incoming inspection at formulation facilities.
On-site pre-qualification support addresses customer-specific needs, particularly for those requiring low-endotoxin or micro-series packaging types. Extensive application testing can be arranged to help users achieve optimal downstream performance, whether for direct compression tablets or alternative delivery forms. For formulations sensitive to trace-level contaminants, additional control samples are provided, along with impurity trending data to meet labelling or validation requirements. Tailored advice covers material compatibility with excipients and guidance for reprocessing off-specification batches.
Support teams ensure full traceability for every lot, from raw material receipt through shipment, enabling root cause analysis in case of deviations. Batch-level documentation includes process route, change control history, and results from all critical control points. For customers participating in ongoing clinical trials or those requiring post-market surveillance, additional stability monitoring and extended data reporting are available. Return or replacement procedures follow pre-defined quality assurance protocols, ensuring minimal disruption and clear corrective actions in response to quality events.
Doxifluridine production requires stringent process management and deep industry expertise. As the direct manufacturer, we oversee every aspect of synthesis, purification, and grading. Production takes place in controlled, audited facilities using proprietary methodologies designed for reliable, batch-to-batch output. Our plants run under strict GMP conditions and maintain documented traceability for each lot released. Technical parameters align with prevailing pharmacopoeial standards, and all output undergoes analytical testing in our in-house laboratories.
Doxifluridine acts as a strategic intermediate for oral 5-FU prodrugs and is widely integrated into the manufacture of antineoplastic pharmaceuticals. Formulators in oncology research and production teams in finished dose facilities rely on this compound for solid and liquid preparations. Downstream users in the API and finished dosage sectors entrust production to direct manufacturers with a demonstrated track record in process consistency.
Maintaining consistent quality ranks as a core focus on every production cycle. Analytical teams implement HPLC, NMR, and additional techniques to confirm assay, identity, and impurity thresholds. Each lot leaves our facility only after meeting tightly defined criteria for purity, moisture, and particle characteristics. We operate certified release systems that confirm both compliance and reproducibility. End users see measurable benefits from stable input materials which support efficient process validation and regulatory submission.
All packaging takes place in climate-managed areas to safeguard product integrity. Sealed primary containers resist moisture intrusion and external contamination. Bulk totes as well as smaller pack sizes enable flexible, scalable logistics for both R&D and commercial-scale needs. Our controlled inventory system minimizes lead times and supports reliable dispatch to domestic and international partners. Regular output volumes and scheduled campaign runs allow business buyers to coordinate procurement with confidence.
Direct access to our technical team streamlines any troubleshooting or integration needs. Production chemists and support staff address formulation or compatibility questions based on real-world process data. Process engineers at industrial buyers benefit from timely responses on solubility, compatibility, and analytical queries. Manufacturing clients regularly request collaborative support during scale-up and product transfer activities, where hands-on process experience often solves complex technical challenges.
Pharmaceutical developers, manufacturers, and procurement teams optimize value by sourcing at the point of origin. Direct shipping from our facility means faster response times and controlled risk in supply assurance. Contracting with a manufacturing source avoids hidden markups and minimizes communication lag. The technical and commercial interface ensures that each requirement—whether analytical documentation, regulatory support, or scheduling flexibility—receives immediate attention from the production side.
| Key Area | Direct Manufacturer Advantage |
|---|---|
| Production Oversight | Full in-house process control for every batch |
| Quality Assurance | Certified labs, analytical testing, traceable documentation |
| Packaging | Climate management, secure containment, scale flexibility |
| Technical Service | Direct support from production chemists and process engineers |
| Supply Stability | Planned inventory cycles, consistent lead times |
Experience in Doxifluridine manufacturing translates to reduced uncertainty for partners across the pharmaceutical industry supply chain. A direct producer’s expertise supports reliable project timelines and strengthens business continuity for API, formulation, and distribution operations.
In the production of Doxifluridine, we focus heavily on its pharmacological profile to ensure every batch meets both quality and functional expectations. Chemically, Doxifluridine serves as a prodrug of 5-fluorouracil (5-FU). After administration, it undergoes enzymatic conversion, primarily through pyrimidine nucleoside phosphorylase, into the active form—5-FU. This metabolic activation happens preferentially in tumor tissues, which have increased enzyme activity relative to most normal tissues.
The released 5-FU blocks thymidylate synthase, interrupting DNA synthesis in rapidly dividing cells and resulting in cytotoxicity for malignant cells. This mechanism underpins the medical value of Doxifluridine in oral chemotherapy regimens, especially for gastrointestinal cancers. During product development, we prioritize this conversion efficiency and tune our production parameters—solvent selection, crystallization timing, and purification steps—to maximize consistency batch to batch.
Stability stands as a significant concern during the journey from synthesis to final dosage form. Doxifluridine’s structure contains a glycosidic bond that is prone to hydrolysis, especially in the presence of water or under acidic or basic conditions. Through multiple pilot batches, our technical team observed that exposure to humidity or elevated temperatures during formulation or storage promotes degradation, evident by the increase of 5-FU and related impurities in stability testing.
We mitigate hydrolytic breakdown by controlling environmental exposure rigorously during drying, milling, and tableting. Our standard packaging involves using moisture-barrier materials and desiccants, with temperature recommendations clearly stated based on our long-term stability data. Control of moisture content throughout blending and compression stages directly affects shelf life and product integrity, so we enforce periodic digital moisture analysis and strict clean-room procedures.
Doxifluridine’s oral bioavailability significantly exceeds direct 5-FU administration. Yet, maintaining active content in tablets, capsules, or suspensions relies on formulation strategies that inhibit early degradation. We learned from in-process testing that excipient compatibility poses a challenge; excipients with residual moisture or free acids can trigger unwanted hydrolysis. Our R&D selects only excipient grades proven by accelerated stability studies to show no catalytic effect on degradation pathways.
Film coating not only masks the drug’s taste, it also provides an additional moisture shield. We validate each coating system in-house for its performance over the labeled shelf life in simulated storage environments. Importantly, all excipients and packaging materials are sourced from vetted suppliers who meet our rigorous quality criteria, ensuring low risk of cross-contamination and foreign impurity introduction.
Continuous improvement remains embedded in our GMP systems. We regularly implement new analytical methods for even earlier detection of trace degradation and run forced degradation studies to map out all possible failure modes. These findings feed directly into our annual process review and inform updates in batch records, training, and risk mitigation protocols.
We understand oncologists, pharmacists, and patients rely on stable, consistent supply. Our manufacturing investment focuses on precision controls and real-time release testing to keep Doxifluridine product quality aligned with current regulatory and therapeutic needs. Further technical consultation or product samples can be arranged through our technical support division for formulation partners exploring advanced oral dosage concepts.
In the dynamic landscape of specialty pharmaceuticals, procurement practices for active ingredients like Doxifluridine have real consequences on both production schedules and commercial planning. For Doxifluridine, we approach each inquiry with a clear focus on operational transparency. Our objective is to create a reliable supply chain for our clients who require absolute assurance on production delivery and regulatory compliance.
Over the years, we have determined a minimum order quantity for Doxifluridine that achieves balance between cost efficiency and inventory management. MOQs are not arbitrary for us—they reflect real-life considerations: process yield, packaging standards, and logistics. For Doxifluridine, the MOQ typically stands at 1 kilogram for new clients. This threshold arises from our batch manufacturing capability and the need to preserve the compound’s chemical stability from production through transportation. Smaller orders make it difficult to assure consistency in analytical quality and batch validation, so our MOQ policy also stems from years of collaboration with formulators and regulatory agencies.
From raw materials to finished Doxifluridine, every stage in our production process comes under strict quality control and traceability. Standard lead times range from 6 to 8 weeks after contract confirmation. This window covers raw material sourcing, synthesis, in-process controls, full release analytical testing, and regulatory documentation. Our entire supply chain—from supplier audits to in-house synthesis—remains dedicated to traceability and batch documentation. We are often asked to expedite production for clinical projects or off-schedule launches, and in some cases, we can compress the lead time to 4 weeks, provided we have approved forecasts or annual contracts in place.
Setting a MOQ and lead time is not about convenience on our end; it is about aligning customer expectations with real laboratory and plant realities. Shortcuts in MOQ almost always introduce risk—whether that is in terms of stability, cost per unit, or even contamination. The pharmaceutical supply chain relies on predictability and precision. When customers plan ahead and work with our standard terms, we deliver repeatable outcomes, batch-to-batch consistency, and optimal cost structure.
For customers in the early stages of R&D, we support preclinical requirements by offering sampler packs where regulatory and operational feasibility allow. Our technical team can sometimes provide splits from validated production lots, as long as quality and traceability are maintained. For scale-up and commercial-scale projects, bulk orders are supported with robust documentation, full CoA, DMF support, and technical dossiers.
Our position as a manufacturer gives us control over every step, from raw material qualification through QA release and logistics. This allows us to provide honest timelines, relevant technical support, and the confidence that each gram produced and shipped meets or exceeds regulatory expectations. By investing in long-term supply programs and close communication, we give our customers stronger predictability in planning their own manufacturing and clinical rollouts.
Doxifluridine draws close attention during shipping and storage because of its pharmaceutical profile and the strict standards involved in its handling. Our daily operations at the production facility focus on maintaining active substance integrity and personnel safety. This comes from experience—not just regulatory obligation.
A tightly controlled environment always serves as our starting point. Doxifluridine’s stability can change if exposed to light, moisture, or temperature variations. In our facility, we maintain dry, cool conditions and rely on temperature monitoring systems in storage areas. Our team reviews the calibration logs regularly. Any deviation prompts an immediate review of stored product batches. For light sensitivity, we stick with sealed opaque containers and avoid unnecessary transfers until product leaves for shipping. Segregated storage areas ensure incompatible chemicals do not come into contact with APIs like Doxifluridine.
We use robust, tamper-evident packaging designed to withstand transit route uncertainties. Each shipment includes clear labelling that identifies the compound, hazard classes, and necessary emergency information. Temperature during transit is monitored with data loggers where regulations or customer requirements dictate. Partnering with experienced logistics agents who understand pharmaceutical cargo nuances limits risk. Shipping manifests include batch traceability data, which allows us to track the journey and intervene if transit delays threaten product stability. We schedule shipments according to weather and route risk, particularly in regions prone to temperature excursions. Our shipping containers are never reused for other chemicals, reducing any cross-contamination risk.
Shipping Doxifluridine draws oversight from multiple agencies, including pharmaceutical-specific and chemical transport authorities. We maintain up-to-date Material Safety Data Sheets and Certificates of Analysis with every batch, always referencing the latest global pharmacopoeial guidelines. Our staff receives standardized training on hazard communication and emergency response. Inspection routines include cross-checks for correct labelling, consignment documentation, and packaging integrity. Each export batch passes an internal compliance checklist before it moves off our site. Customs and port authority rules can shift, so our regulatory affairs group monitors new developments in key export markets. When rules evolve, we update our standard operating procedures so that batches always move in accordance with the law. For controlled substance regulations in certain countries, we prepare additional paperwork and coordinate directly with health authorities well before shipping dates.
Delayed shipments or customs holdups sometimes test our planning. We address these risk factors by maintaining safety stock in areas with high demand. If local regulation diverges from international standards, our technical and quality staff work with third-party auditors to close gaps rapidly. Documentation errors in the past cost days in customs—a lesson we folded into our compliance checklist. We prioritize transparency with our customers; batch documentation packages can be tailored for the client’s regulatory environment. Continuous feedback from our logistics and quality assurance teams feeds process improvements: everything from new container seals to revised training drills.
Direct experience with Doxifluridine at every stage—from synthesis to delivery—shapes our approach. We see careful storage, secure shipping, and disciplined regulatory compliance as non-negotiable factors, not just legal requirements. This keeps both people and product safe throughout the supply chain.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
